Zhongping Capital
中平资本
elsewhere's corpus has no standalone profile of Zhongping Capital — it only shows up in the fund-flow news of other investors' coverage. Per a Gaorong Ventures report, Zhongping Capital led a nearly 500 million yuan new round for innovative drug developer CasCade Therapeutics (KSKD) in February 2026, alongside Guoshou Capital, Qingsong Capital and Qingdao Guoxin ; the company had raised close to 1 billion yuan over the prior 10 months . It also appeared as a co-investor — alongside CDH VGC, CICC Capital, CMC Capital and others — in a round for VAST, per an Oasis Capital piece from September 2026 . On the strength of that material, it reads as an active financial investor participating in both healthcare and tech rounds in 2026, but elsewhere doesn't cover its founding, team, or fund size.
AI-generated — may contain errors, please verify.
Coverage
From 30 Million to 3 Billion: Three Rounds, Wanwu Capital | Luzhou Shengmingli
VAST recently announced the completion of its Series B and B+ funding rounds.
Rongbao | Karl Dynamics, Aerofugia, StarsComm, and ImmuPeak Kick Off the Year with Major Funding Rounds
Leading the industry into a new era.
CasCade Therapeutics Closes Nearly 500 Million Yuan Major Funding Round, Targeting Nuclear Receptor and GPCR Innovative Drug R&D
Dedicated to becoming a global leader in metabolic disease therapeutics.
Setting Off in Spring: 7 Early-Stage Companies Raise Over 800 Million | FreeS Family Funding News · Vol 14
Looking forward to working with more outstanding founders.
